NEXT Financial Group Inc reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 63.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,092 shares of the biopharmaceutical company’s stock after selling 10,508 shares during the period. NEXT Financial Group Inc’s holdings in Gilead Sciences were worth $494,000 at the end of the most recent reporting period.
Other hedge funds also recently added to or reduced their stakes in the company. Keel Point LLC grew its holdings in Gilead Sciences by 0.4% in the second quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock worth $221,000 after purchasing an additional 12 shares during the period. Paradigm Financial Advisors LLC grew its holdings in Gilead Sciences by 0.3% in the second quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock worth $617,000 after purchasing an additional 26 shares during the period. Princeton Portfolio Strategies Group LLC grew its holdings in Gilead Sciences by 0.4% in the second quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock worth $691,000 after purchasing an additional 41 shares during the period. Arrow Financial Corp grew its holdings in Gilead Sciences by 0.3% in the second quarter. Arrow Financial Corp now owns 17,771 shares of the biopharmaceutical company’s stock worth $1,258,000 after purchasing an additional 45 shares during the period. Finally, Auxier Asset Management grew its holdings in Gilead Sciences by 1.4% in the second quarter. Auxier Asset Management now owns 6,773 shares of the biopharmaceutical company’s stock worth $479,000 after purchasing an additional 96 shares during the period. 76.47% of the stock is owned by institutional investors.
A number of brokerages have weighed in on GILD. Mizuho restated a “buy” rating and issued a $95.00 price objective (up previously from $83.00) on shares of Gilead Sciences in a report on Monday. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 price objective on the stock in a report on Monday. BMO Capital Markets upped their price objective on shares of Gilead Sciences from $86.00 to $88.00 and gave the stock a “market perform” rating in a report on Thursday. Credit Suisse Group set a $80.00 price objective on shares of Gilead Sciences and gave the stock a “hold” rating in a report on Wednesday, February 7th. Finally, Citigroup restated a “buy” rating and issued a $105.00 price objective (up previously from $103.00) on shares of Gilead Sciences in a report on Thursday. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $87.04.
In other news, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $74.64, for a total transaction of $1,119,600.00. Following the sale, the executive vice president now directly owns 70,988 shares in the company, valued at approximately $5,298,544.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman John C. Martin sold 50,000 shares of the firm’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $83.56, for a total transaction of $4,178,000.00. Following the sale, the chairman now owns 3,046,766 shares in the company, valued at $254,587,766.96. The disclosure for this sale can be found here. Insiders sold 358,333 shares of company stock worth $28,066,908 over the last quarter. Insiders own 1.30% of the company’s stock.
Gilead Sciences, Inc. (NASDAQ:GILD) traded up $0.82 on Monday, reaching $80.14. 9,972,034 shares of the company’s stock traded hands, compared to its average volume of 9,910,000. The company has a quick ratio of 3.48, a current ratio of 3.55 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $89.54. The company has a market capitalization of $104,660.00, a P/E ratio of 23.03, a PEG ratio of -1.77 and a beta of 1.22.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The business had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $5.71 billion. During the same period last year, the firm earned $2.70 earnings per share. The company’s quarterly revenue was down 18.7% on a year-over-year basis. research analysts expect that Gilead Sciences, Inc. will post 6.41 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be given a $0.57 dividend. The ex-dividend date is Thursday, March 15th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a yield of 2.85%. Gilead Sciences’s dividend payout ratio (DPR) is presently 59.77%.
TRADEMARK VIOLATION NOTICE: This story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/12/next-financial-group-inc-trims-holdings-in-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.